Aligos Therapeutics (ALGS) Non-Current Deffered Revenue (2020 - 2022)
Aligos Therapeutics' (ALGS) quarterly Non-Current Deffered Revenue came in at $1.6 million in Q3 2022, up 13.49% YoY from $1.4 million in Q3 2021, and down 52.17% on a QoQ basis from $3.3 million in Q2 2022.
Aligos Therapeutics (ALGS) Non-Current Deffered Revenue (2020 - 2022) Analysis & Trends
Aligos Therapeutics (ALGS) has 3 years of Non-Current Deffered Revenue data on file, last reported at $1.6 million in Q3 2022.
- Quarterly Non-Current Deffered Revenue rose 13.49% year-over-year to $1.6 million in Q3 2022, while the trailing twelve-month figure through Sep 2022 was $1.6 million (up 13.49% YoY) and the FY2020 annual result came in at $4.1 million, changed N/A from the prior year.
- Non-Current Deffered Revenue slipped to $1.6 million in Q3 2022, from $3.3 million in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $5.0 million in Q1 2022 to a low of $1.4 million in Q3 2021.
- A 3-year average of $3.1 million and a median of $3.3 million in 2022 frame the typical range for Non-Current Deffered Revenue.
- The widest YoY moves for Non-Current Deffered Revenue: up 42.83% in 2022, down 13.49% in 2022.
- Tracing ALGS's Non-Current Deffered Revenue over 3 years: stood at $4.1 million in 2020, then sank by 66.63% to $1.4 million in 2021, then climbed by 13.49% to $1.6 million in 2022.
- The last three Non-Current Deffered Revenue figures came in at $1.6 million (Q3 2022), $3.3 million (Q2 2022), and $5.0 million (Q1 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 147.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Aligos Therapeutics | 68.90 Mn | 38.45 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 1.56 Mn |
| Jun 30, 2022 | 3.25 Mn |
| Mar 31, 2022 | 5.01 Mn |
| Sep 30, 2021 | 1.37 Mn |
| Jun 30, 2021 | 2.73 Mn |
| Mar 31, 2021 | 3.51 Mn |
| Dec 31, 2020 | 4.11 Mn |